Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Protein tyrosine phosphatase SHP2, encoded by PTPN11, is a key regulator in cellular signaling pathways.
• SHP2's complex roles present challenges but also opportunities for cancer therapy development.
• Numerous strategies targeting SHP2 have emerged due to its biological significance in cancer.

Purpose of the Study:

• To provide a comprehensive overview of current strategies for targeting SHP2 in cancer therapy.
• To discuss various therapeutic modalities including inhibitors, activators, and PROTAC degraders.
• To highlight combination strategies for enhanced SHP2-targeted cancer treatment.

Main Methods:

• Review and synthesis of recent research on SHP2-targeting strategies.
• Analysis of clinical trial progress for SHP2 inhibitors.
• Discussion of protein-protein interaction targeting and combination therapies.

Main Results:

• Eight SHP2 inhibitors have progressed to clinical trials for solid tumors and adaptive resistant cancers.
• Diverse strategies, including small molecule inhibitors, activators, and PROTAC degraders, are being explored.
• Targeting SHP2 protein-protein interactions and implementing combination therapies show promise.

Conclusions:

• Targeting SHP2 offers a promising avenue for cancer treatment.
• A range of therapeutic approaches are under investigation, with several inhibitors in clinical development.
• Future directions involve optimizing combination strategies tailored to specific targets and pathways for improved efficacy.